Unknown

Dataset Information

0

TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy.


ABSTRACT: Immunotherapy for cancer is making impressive strides at improving survival of a subset of cancer patients. To increase the breadth of patients that benefit from immunotherapy, new strategies that combat the immunosuppressive microenvironment of tumors are needed. Phosphatidylserine (PS) signaling is exploited by tumors to enhance tumor immune evasion and thus strategies to inhibit PS-mediated immune suppression have potential to increase the efficacy of immunotherapy. PS is a membrane lipid that flips to the outer surface of the cell membrane during apoptosis and/or cell stress. Externalized PS can drive efferocytosis or engage PS receptors (PSRs) to promote local immune suppression. In the tumor microenvironment (TME) PS-mediated immune suppression is often termed apoptotic mimicry. Monoclonal antibodies (mAbs) targeting PS or PSRs have been developed and are in preclinical and clinical testing. The TIM (T-cell/transmembrane, immunoglobulin, and mucin) and TAM (Tyro3, AXL, and MerTK) family of receptors are PSRs that have been shown to drive PS-mediated immune suppression in tumors. This review will highlight the development of mAbs targeting PS, TIM-3 and the TAM receptors. Video Abstract.

PROVIDER: S-EPMC7036251 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC7047187 | BioStudies
| S-EPMC2757006 | BioStudies
| S-EPMC8641883 | BioStudies
| S-EPMC6999836 | BioStudies
| S-EPMC3572209 | BioStudies
| S-EPMC8454703 | BioStudies
| S-EPMC6139056 | BioStudies
| S-EPMC9115604 | BioStudies
| S-EPMC6297748 | BioStudies
2018-01-01 | S-EPMC5988690 | BioStudies